- Home
- DPG vs CAPR Comparison
DPG vs CAPR Comparison
Compare DPG & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DPG
- CAPR
- Stock Information
- Founded
- DPG 2011
- CAPR 2005
- Country
- DPG United States
- CAPR United States
- Employees
- DPG N/A
- CAPR N/A
- Industry
- DPG Trusts Except Educational Religious and Charitable
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DPG Finance
- CAPR Health Care
- Exchange
- DPG Nasdaq
- CAPR Nasdaq
- Market Cap
- DPG 457.8M
- CAPR 392.8M
- IPO Year
- DPG N/A
- CAPR N/A
- Fundamental
- Price
- DPG $12.16
- CAPR $14.33
- Analyst Decision
- DPG
- CAPR Strong Buy
- Analyst Count
- DPG 0
- CAPR 7
- Target Price
- DPG N/A
- CAPR $39.29
- AVG Volume (30 Days)
- DPG 150.1K
- CAPR 1.5M
- Earning Date
- DPG 01-01-0001
- CAPR 05-12-2025
- Dividend Yield
- DPG 9.09%
- CAPR N/A
- EPS Growth
- DPG N/A
- CAPR N/A
- EPS
- DPG N/A
- CAPR N/A
- Revenue
- DPG N/A
- CAPR $22,270,465.00
- Revenue This Year
- DPG N/A
- CAPR $78.85
- Revenue Next Year
- DPG N/A
- CAPR $157.99
- P/E Ratio
- DPG N/A
- CAPR N/A
- Revenue Growth
- DPG N/A
- CAPR N/A
- 52 Week Low
- DPG $7.90
- CAPR $3.52
- 52 Week High
- DPG $13.58
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- DPG 56.81
- CAPR 66.78
- Support Level
- DPG $11.60
- CAPR $9.43
- Resistance Level
- DPG $12.20
- CAPR $10.09
- Average True Range (ATR)
- DPG 0.44
- CAPR 0.93
- MACD
- DPG 0.07
- CAPR 0.67
- Stochastic Oscillator
- DPG 91.85
- CAPR 98.74
About DPG Duff & Phelps Utility and Infrastructure Fund Inc.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund. Its investment objective is to seek total return, resulting primarily from a high level of current income, with an emphasis on providing tax-advantaged dividend income.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.